arrow
J

John Reynolds

Alfred Health
H指数:59
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years

一项结合米哚妥林、低剂量阿糖胞苷和维奈克拉的新诊断AML(≥60岁)患者的随机Ⅱ期研究

Blood
IF23.1
2026-01-010
PRE
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL

ALLG APML5:三氧化二砷口服生物利用度及安全性评估,评估时间在APL巩固治疗期间

2025-01-281
OA
Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM)- the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

来自Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM)—FRAIL-M研究(AMaRC 19-01; ALLG MM22)的初步结果

BLOOD
IF23.1
2024-11-050
PRE
A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax plus /- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

一项比较低剂量阿糖胞苷和维奈克拉联合/不联合米哚妥林治疗非不良染色体风险急性髓系白血病的II期随机试验:ALLG AMLM25干预试验

BLOOD
IF23.1
2024-11-050
PRE
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
2024-05-141
OAAI
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation
2023-06-055
OAAI
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
LEUKEMIA
IF13.4
2022-04-2214
OAAI